

PRESS RELEASE 28 April 2009

## **Resolutions from Biovitrums AGM**

**The Biovitrum Annual General Meeting (AGM) convened earlier today in Stockholm and voted in favour of all resolutions proposed at the meeting, including:**

The AGM approved the proposal to carry forward the retained profits of SEK 388,501,778.

The AGM discharged the members of the Board and the President from liability for the fiscal year 2008.

The ordinary Board Members Håkan Åström, Wenche Rolfsen, Michael Steinmetz, Hans Wigzell and Mats-Olof Ljungkvist were re-elected and Peter Sellei and Hans Glemstedt were elected as new board members. Håkan Åström was elected Chairman of the Board.

Anders Hultin and Toni Weitzberg have declined re-election. Peter Sellei is responsible for the Healthcare Sector in the Core Investment Department at Investor AB and former thoracic surgeon at Karolinska Hospital and pharma analyst. Sellei has an M.D. from Karolinska Institutet. Hans Glemstedt is a team member in the Operating Investment group of Investor AB and former Senior Manager at McKinsey. Glemstedt has a graduate and MBA from Stockholm School of Economics.

The AGM approved the compensation to the Board totaling SEK 2,650,000, of which SEK 950,000 is paid to the Chairman, and SEK 250,000 is paid to each of the other Board Members. The compensation for work in the committees of the Board was approved at SEK 50,000 to the chairman of the Audit Committee and SEK 25,000 to the other members of the Audit Committee and that no compensation will be received by the members of the Remuneration Committee. The AGM also approved compensation for work in the Scientific Committee at SEK 50,000 to the Chairman and SEK 25,000 to each of the other members in the committee.

The AGM approved the guidelines for remuneration, etc. for the Management.

The AGM decided to approve the proposed instructions and charter for the Nomination Committee.

The AGM decided to adopt the Board's proposal regarding amendments in the articles of association in respect of announcement of notice. The amendment is conditional upon that the provisions of the Companies Act (SFS 2005:551) regarding notice to general meeting will be amended.

Furthermore, the AGM decided to authorize the Board to resolve to issue new shares.

The AGM approved Biovitrum's new performance based, long-term share program for 2009 ("Share Program 2009") comprising a resolution regarding a directed issue of series C shares and a resolution regarding authorization for the Board to repurchase issued series C shares. The program includes up to 50 managers and key employees, which receive the possibility to be allocated common shares in Biovitrum free of charge. An offer to participate in the program shall be provided no later than 31 December 2009. The participants of the program are divided into three categories: members of the management team and two additional categories for other managers and key employees. For each category, the board of directors will determine a maximum value for the Share Program 2009 related to the participant's salary. The respective maximum value is, thereafter, converted to a maximum number of common shares to be allocated. With an assumed share price of SEK 52 for the Biovitrum common share the maximum number of common shares to be allocated amounts to 350,000. The board of directors resolves on the number of common shares that shall be possible to receive free of charge, after nomination from the Compensation & Benefits committee. The program participants are nominated based on competence and performance as well as taking into consideration the strategic

importance of retaining key employees within the business. The outcome of the Share Program 2009 is dependent on the fulfillment of targets for value creation, determined by the board of directors, connected to the total shareholder return of the Biovitrum common share, during a three year period as from the date of the offer to participate in the program. The board of directors has allowed for a preliminary calculation of the theoretical value of the right to receive allocation of common shares in Biovitrum free of charge. Assuming a market price of SEK 52 and based on probability assessments as regards the achievement of the conditions as set out above, the value amounts to SEK 20.70 (39.8% of SEK 52), which can lead to a maximum cost for Share Program 2009 of approximately MSEK 7.3. Based on the theoretical assumption of an annual 10% increase in the share price of SEK 52 and on the assumption that the program participants receive maximum number of shares, the social security charges for Share Program 2009 are estimated to amount to approximately MSEK 8.0.

At the statutory meeting of the Board held in conjunction with the AGM, Mats-Olof Ljungkvist (Chairman), Peter Sellei and Håkan Åström were elected to the Audit Committee, and Hans Glemstedt (Chairman), Håkan Åström and Michael Steinmetz to the Remuneration Committee. Michael Steinmetz (Chairman), Hans Wigzell and Wenche Rolfsen were elected to the Scientific Committee.

For full details on each proposal adopted by the AGM please refer to [www.biovitrum.com](http://www.biovitrum.com) where documentation related to the AGM is published.

President and CEO Martin Nicklasson address to the meeting will be available at [www.biovitrum.com](http://www.biovitrum.com).

**For more information, contact:**

Martin Nicklasson, CEO  
Phone: +46 8 697 2545

Göran Arvidson, CFO  
Cell phone: +46 8 697 23 27

Erik Kinnman, VP Investor Relations  
Cell phone: +46 73 422 15 40  
[erik.kinnman@biovitrum.com](mailto:erik.kinnman@biovitrum.com)

**About Biovitrum**

Biovitrum is a Swedish pharmaceutical company. The company markets a range of specialist pharmaceuticals internationally. Using its expertise and experience Biovitrum takes scientific innovation all the way to the market and to specialist indication patients with significant medical need. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within our prioritized areas of hemophilia, inflammation/autoimmune diseases and malabsorption. The company has revenues of approximately SEK 1.2 billion and around 400 employees. It is listed on the OMX Nordic Exchange in Stockholm. For more information go to [www.biovitrum.com](http://www.biovitrum.com).